© 2025 HSP News Service, L.L.C.
ASCO EXPERT Sumanta K. Pal, MD, of City of Hope, Duarte, California, commented, “IMmotion 151 is a positive trial and represents an important breakthrough. We have debated combination treatment strategies for advanced kidney cancer. This study looks at the combination of a programmed cell death...
THE TYROSINE KINASE inhibitor sunitinib (Sutent) has been the mainstay of treatment for first-line treatment of advanced renal cell carcinoma for about a decade. The IMmotion151 study reported at the 2018 Genitourinary Cancers Symposium found that the combination of the immune checkpoint inhibitor...
Preliminary results from the phase II portion of the TiNivo study, a phase Ib/II multicenter trial of oral tivozanib in combination with intravenous (IV) nivolumab (Opdivo) for the treatment of metastatic renal cell carcinoma (RCC) were presented by Escudier et al at the 2018 Genitourinary Cancers...
In a study reported in the Journal of Clinical Oncology, Cella et al found little difference in quality-of-life (QOL) outcomes between the cabozantinib (Cabometyx) and everolimus (Afinitor) groups in the phase III METEOR trial. The study investigated these treatments in patients with metastatic...
Patrick Schöffski, MD, MPH, of Catholic University Leuven, discusses findings on the effect of crizotinib on disease control in patients with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification (Abstract 580).
Sumanta K. Pal, MD, of the City of Hope Comprehensive Cancer Center, discusses phase III study findings from IMmotion151, which looked at atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (RCC), and results from a safety and efficacy trial of axitinib in combination with pembrolizumab with advanced RCC (Abstracts 578 & 579).
Daniel J. George, MD, of Duke University Medical Center, discusses phase III findings on adjuvant sunitinib in patients with high-risk renal cell carcinoma, in an exploratory pharmacogenomic analysis (Abstract 576).
Daniel J. George, MD, of Duke University Medical Center, discusses study findings on cabozantinib vs sunitinib for previously untreated patients with advanced renal cell carcinoma of intermediate or poor risk, in a subgroup analysis of progression-free survival and objective response rates (Abstract 582).
Laurence Albiges, MD, PhD, of the Gustave Roussy Cancer Centre, discusses study findings on the safety and efficacy of nivolumab in metastatic renal cell carcinoma (Abstract 577).
Data on CB-839, a first-in-class glutaminase inhibitor, will be presented by Tannir et al at the 2018 Genitourinary Cancers Symposium in San Francisco (Abstract 603). The data are from the CX-839-001 study, which includes cohorts evaluating the safety, efficacy and recommended phase II dose of ...
Combining the antiangiogenic agent axitinib (Inlyta) with the immunotherapy pembrolizumab (Keytruda) was found to have promising antitumor activity and no unexpected side effects in an early-phase clinical trial in patients with advanced kidney cancer who had not been previously treated. The full...
In a phase III clinical trial of patients with previously untreated metastatic renal cell cancer combining the immunotherapy atezolizumab (Tecentriq) with the targeted therapy bevacizumab (Avastin) delayed cancer growth by about 3 months longer than sunitinib, another targeted therapy. The benefit...
Sumanta K. Pal, MD, of the City of Hope, discusses immunotherapy as a front-line treatment for kidney cancer and the strategy of VEGF blockade with immunotherapy, which is emerging as a possible treatment modality.
As reported in the Journal of Clinical Oncology, Motwani et al have developed a predictive model for acute kidney injury following a first course of cisplatin that includes patient age, cisplatin dose, hypertension, and serum albumin level. Study Details The study involved data from 2,118...
BREAST CANCER Survival in Metastatic Triple-Negative Breast Cancer Explored in Retrospective Study In a study reported in the Journal of Clinical Oncology, Stover et al found that cell-free (cf) DNA tumor fraction ≥ 10% was associated with worse survival in metastatic triple-negative breast...
In a subgroup analysis of the phase III METEOR trial of advanced renal cell carcinoma (RCC) patients with with bone metastases, cabozantinib was associated with improved outcomes vs everolimus. The analysis was reported by Escudier et al in the Journal of Clinical Oncology. Study Details In the...
On January 9, Eisai and Merck announced that they received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for Eisai's multiple receptor tyrosine kinase inhibitor lenvatinib (Lenvima) in combination with Merck's anti–programmed cell death protein 1...
In a phase I trial reported in the Journal of Clinical Oncology, Courtney et al found that a first-in-class hypoxia-inducible factor-2α (HIF-2α) antagonist (PT2385) was active in patients with previously treated advanced clear cell renal cell carcinoma (RCC). Study Details In the...
On December 21, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to avelumab (Bavencio) in combination with axitinib (Inlyta) for treatment-naive patients with advanced renal cell carcinoma. “A combination approach with an immunotherapy, whose activity may ...
On November 16, 2017, sunitinib malate (Sutent) was approved for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy.1,2 Supporting Efficacy Data Approval was based on the findings of the double-blind phase III S-TRAC trial in which 615...
On December 19, 2017, the U.S. Food and Drug Administration (FDA) granted regular -approval to cabozantinib -(Cabometyx) for treatment of patients with advanced renal cell carcinoma (RCC). The FDA previously approved cabozantinib in 2016 for treatment of patients with advanced RCC who have...
On December 19, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to cabozantinib (Cabometyx) for treatment of patients with advanced renal cell carcinoma (RCC). The FDA previously approved cabozantinib in 2016 for treatment of patients with advanced RCC who have received...
On December 13, the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) for priority review of nivolumab (Opdivo) plus ipilimumab (Yervoy) to treat intermediate- and poor-risk patients with advanced renal cell carcinoma. The FDA also previously...
An analysis from the Children’s Oncology Group Study AREN0532 reported in the Journal of Clinical Oncology by Fernandez et al showed that positive lymph nodes and loss of heterozygosity (LOH) at chromosome 1p or 16q are associated with poorer event-free survival in patients with stage III...
Action to Cure Kidney Cancer (ACKC) was instrumental in securing a $10 million line item for the Kidney Cancer Research Program as part of the Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP). This represents the largest increase ever in the...
Today, the U.S. Food and Drug Administration (FDA) approved sunitinib malate (Sutent) for the adjuvant treatment of adult patients who are at a high risk of recurrent renal cell carcinoma after nephrectomy. “This is the first adjuvant treatment approved for patients with renal cell...
As reported in the Journal of Clinical Oncology, Ho et al found that tumor-based enhancer of zeste homolog 2 (EZH2) gene or protein expression was independently predictive of prognosis in localized clear cell renal cell carcinoma. EZH2 is a chromatin remodeler implicated in the pathogenesis of...
On October 16, the U.S. Food and Drug Administration (FDA) determined the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for patients with previously untreated advanced renal cell carcinoma (RCC) to be sufficiently complete to permit a substantive review. The FDA granted...
FORMAL DISCUSSANT, Manuela Schmidinger, MD, of the Medical University of Austria, Vienna, commented on the CheckMate 214 findings. “We have just seen a change in the paradigm in the treatment of metastatic renal cell cancer.” “More than a decade ago, VEGF [vascular endothelial growth factor]...
A CHANGE IN PARADIGM may be on the horizon for the treatment of metastatic renal cell carcinoma. According to the results of CheckMate 214, the combination of ipilimumab (Yervoy) plus nivolumab (Opdivo) outperformed the standard of care—sunitinib (Sutent)—for first-line treatment, with improved...
Gerard Morton, MD, of Sunnybrook Odette Cancer Centre, summarizes a session that included discussion of late toxicities of radiotherapy for locally recurrent prostate cancer; using chemotherapy instead of radiation in early-stage seminoma; radiotherapy vs surgery plus radiotherapy in Gleason score 9–10 prostate cancer; and an analysis of the IROCK study on kidney cancer (Abstracts 1, 1089, 282, 330).
As reported in the Journal of Clinical Oncology by Motzer et al, the phase III PROTECT trial showed no significant disease-free survival benefit for adjuvant pazopanib at 600 mg vs placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma at high risk of relapse. ...
The U.S. Food and Drug Administration today approved bevacizumab-awwb (Mvasi) as a biosimilar to bevacizumab (Avastin) for the treatment of multiple types of cancer. Bevacizumab-awwb is the first biosimilar approved in the U.S. for the treatment of cancer. “Bringing new biosimilars to...
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses updated overall survival results on cabozantinib vs sunitinib as initial targeted treatment for patients with metastatic renal cell carcinoma (Abstract LBA38).
Bernard J. Escudier, MD, of Gustave Roussy, offers a roundup of the important papers on renal cell cancer presented at this year's ESMO Congress.
Robert A. Figlin, MD, of Cedars-Sinai Medical Center, discusses an interim analysis of phase III findings on rocapuldencel-T, an individualized immunotherapy, for newly diagnosed patients with metastatic renal cell carcinoma (Abstract 1137O).
Bernard J. Escudier, MD, of Gustave Roussy, discusses efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups (Abstract LBA5).
Internationally recognized genitourinary oncologist Maha Hussain, MD, FACP, FASCO, was born and reared in Baghdad, Iraq. “I came from a family that stressed the value of higher education and especially medicine. I have three uncles who are physicians, and my father encouraged my three siblings and...
Staying up-to-date in the fast-paced world of oncology literature is a daunting task at best. To assist with that task, The ASCO Post has assembled an assortment of studies recently published in the Journal of Clinical Oncology. The topics range from therapy for stage IV non–small cell lung cancer...
On August 28, AVEO Oncology announced that the European Commission (EC) has approved tivozanib (Fotivda) for the treatment of adult patients with advanced renal cell carcinoma in the European Union plus Norway and Iceland. Tivozanib is indicated for the first-line treatment of adult patients with...
On August 15, Bristol-Myers Squibb Company announced topline results from the CheckMate-214 trial investigating nivolumab (Opdivo) in combination with ipilimumab (Yervoy) vs sunitinib (Sutent) in intermediate- and poor-risk patients with previously untreated advanced or metastatic renal cell...
The phase I CheckMate 016 trial has shown activity of the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) in metastatic renal cell carcinoma. These findings were reported in the Journal of Clinical Oncology by Hammers et al. Study Details In the dose-escalation study, patients were...
THE COMBINATION of checkpoint inhibitors and vascular endothelial growth factor (VEGF) inhibitors is attractive in renal cell carcinoma, said formal discussant of this trial, Hans Hammers, MD, PhD, of the University of Texas Southwestern Medical Center in Dallas. “Twenty-one percent of patients...
THE COMBINATION of atezolizumab (Tecentriq) plus bevacizumab (Avastin) showed promising results as first-line treatment of patients with metastatic renal cell carcinoma, according to a phase II trial called IMmotion 150. Based on these results, the phase III IMmotion 151 trial is comparing...
In a biomarker-based phase II trial reported in the Journal of Clinical Oncology, Choueiri et al found that the MET tyrosine kinase inhibitor savolitinib was active in MET-driven advanced papillary renal cell cancer. Study Details In the trial, 109 patients with locally advanced or metastatic...
Daniel Heng, MD, MPH, of the Tom Baker Cancer Centre and the University of Calgary, and Sumanta K. Pal, MD, of the City of Hope, discuss key findings presented at ASCO: adjuvant pazopanib vs placebo after nephrectomy in patients with locally advanced disease (the PROTECT Trial), and adjuvant sunitinib used to treat high-risk disease.
Bernard J. Escudier, MD, of Gustave Roussy Cancer Campus, and Sumanta K. Pal, MD, of City of Hope, discuss phase III study findings on adjuvant sunitinib used to treat high-risk renal cell carcinoma, which validate the 16-gene Recurrence Score in patients with stage III disease. (Abstract 4508)
Sumanta K. Pal, MD, of City of Hope, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, exchange views on the key papers in renal cell carcinoma presented at ASCO’s 2017 nonprostate GU oral abstract session. (Abstracts 4504, 4505, 4506, 4507, 4508)
Primo Lara, MD, of the University of California, Davis Comprehensive Cancer Center, discusses three top abstracts on treating advanced renal cell carcinoma with epacadostat, pembrolizumab, atezolizumab, bevacizumab, sunitinib, or pazopanib. (Abstracts 4505, 4507, 4515)
As reviewed in this issue of The ASCO Post, a recent issue of the Journal of Clinical Oncology featured an ASCO Clinical Practice Guideline on the management of small renal masses reported by Finelli and colleagues.1 This comprehensive guideline is written by a group of well-regarded and...